Navigation Links
Regulus Therapeutics and Collaborators from NYU Langone Medical Center Publish New Data Demonstrating Clearance of Cholesterol from Bloodstream and Reduction of Atherosclerotic Plaques through Inhibition of microRNA-33
Date:6/6/2011

cine at Regulus. "These studies establish that antagonizing miR-33 with therapeutic anti-miR oligonucleotides can promote regression of atherosclerosis by increasing levels of HDL-C and promoting reverse cholesterol transport. This new paper, and others we have published recently, supports the development of anti-miR-33 as a potential new therapeutic for dyslipidemias, atherosclerosis, and other related metabolic diseases."

In the study, the impact of miR-33 inhibition was evaluated in low density lipoprotein cholesterol receptor deletion (LDLR-/-) hypercholesterolemic mice with already established atherosclerosis to more closely resemble patients in a clinical setting. The mice were treated weekly for four weeks with subcutaneous injections of 10 mg/kg of anti-miR-33 or control anti-miR oligonucleotides. Anti-miR-33 treatment increased HDL-C and enhanced cholesterol transport from peripheral cells to the liver for further excretion into bile and feces. In addition, anti-miR treated mice had a 35% reduction in lesion area of atherosclerotic plaques. Taken together, the results indicated that anti-miR-33 treatment supports the efflux of cholesterol from lesional macrophages and promotes regression of established atherosclerosis. Importantly, no elevations in serum hepatotoxicity markers, aspartate aminotransferase or alanine aminotransferase (AST/ALT) were observed.  

"Our studies with Regulus show that miR-33 inhibition raises circulating HDL-C, promotes removal of excess cholesterol from atherosclerotic plaques, and favorably affects lesion pathology," said Dr. Moore of NYU Langone. "The data establish miR-33 as an attractive therapeutic target for the treatment of atherosclerotic disease."

Regulus controls fundamental patent rights related to miR-33, including the miR-33 sequence and complementary sequences covered in the Tuschl III patent series. Additional Regulus patent rights include compositions of matter for various chemically modif
'/>"/>

SOURCE Regulus Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., ... unmet needs of severely obese patients, today announced ... beloranib, a selective inhibitor of methionine aminopeptidase 2 ... severe form of genetic obesity.  These results showed ... composition, including reductions in body fat content and ...
(Date:1/14/2014)... Jan. 14, 2014 HeartWare International, ... leading innovator of less invasive, miniaturized circulatory support ... heart failure, today announced that it expects revenues ... approximately $53 million, bringing expected full-year 2013 revenues ... revenue growth of 87% for 2013 above 2012 ...
(Date:1/14/2014)... N.J. , Jan. 14, 2014 InformEx, ... event for buyers and sellers of high-value chemistry, will ... conference at the Miami Beach ... http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) More than 3,500 attendees ... will take part in the conference, which includes on-site ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... Echo Therapeutics, Inc. (Nasdaq: ECTE ), ... non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and ... results for the third quarter and nine months ended ... is available through Echo,s website at www.echotx.com . ...
... Fla., Nov. 8, 2011 VR Laboratories LLC ... as chief scientific advisor.  Rothman will head scientific ... manufacture and bring to market world-class botanical consumer, ... foreign and domestic markets. In addition to assisting ...
Cached Medicine Technology:Echo Therapeutics Announces Third Quarter 2011 Financial Results 2Echo Therapeutics Announces Third Quarter 2011 Financial Results 3Echo Therapeutics Announces Third Quarter 2011 Financial Results 4Echo Therapeutics Announces Third Quarter 2011 Financial Results 5James Rothman Named Chief Scientific Advisor at VR Laboratories 2James Rothman Named Chief Scientific Advisor at VR Laboratories 3James Rothman Named Chief Scientific Advisor at VR Laboratories 4
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... says that workers with health insurance cover return to work ... said that research // conducted for it ... by workers returning early from illnesses. ,The current ... needed an operation and 76 uninsured workers. It was found ...
... press that it has completed the vaccination for all the ... // poultry were vaccinated across Vietnam. , ... the Ministry of Agriculture and Rural Development. ,Some ... whereas others received a booster dose for prevention of the ...
... comes a new study that links breakdown of myelin ... of California, Los Angeles (UCLA) researchers showed that genetic ... breakdown, may prove useful in assessing treatments for prevention ... a process uniquely built up in humans, arguably is ...
... Health Minister was issued notice after a complaint that said ... transfers // and appointments for medical and Para ... Justice K Sreedharan and Upa Lok Ayukta N Krishnan Nair ... others. ,Kerala Government Medical Officers Association (KGMOA) has ...
... medicine was safer than western alternatives // has ... watchdog said on Wednesday. ,The leaflet could dissuade ... serious medical conditions, the Advertising Standards Authority (ASA) said. ... claimed that serious medical problems such as cancer could ...
... ENT and Plastic Surgeon Dr. P. Thulasi Das and his ... Fluid (CSF) // leak to a 25 ... The patient was suffering from meningitis. Meningitis is the inflammation ... meningitis is caused by bacterial or fungal infections. Cerebrospinal fluid ...
Cached Medicine News:Health News:Chinese medicine leaflet broke advertising code 2
... Iodine 'Prep' solutions are ... mucous membrane preparation prior ... Povidone Iodine 'Scrub' solutions ... surfactants. Each is effective ...
Triad Plus PVP-I Scrub Solution has broad-spectrum germicidal action.This special formula is designed to help break down body oils and yet limit the bubbles the surfactants allowing easy removal and ...
Aplicare's disposable 1-ounce pouches are designed for individual application and are ideal for reducing waste. They are used in nursing homes, home healthcare settings, blood banks, laboratories, em...
... are designed for individual application and are ... in nursing homes, home healthcare settings, blood ... hospital departments. This unit dose pouch contains ... germicidal and cleansing agent. Hydrogen Peroxide's chief ...
Medicine Products: